InVitroInsider (Vol 4)

#InVitroInsider?(Vol 4)

Welcome to the fourth edition of In Vitro Insider, your trusted resource for the latest advancements, insights, and trends in the in-vitro diagnostics (IVD) market. As the IVD industry continues to grow and transform, it's vital to stay well-informed about the most recent technologies, regulations, and market dynamics.

Whether you're an IVD expert, a researcher, or simply someone passionate about biotechnology, In-Vitro Insider is your gateway to gaining the knowledge and expertise needed to stay ahead of the curve. In each edition, we will bring you up-to-date news from the world of IVD, exploring cutting-edge diagnostic technologies and highlighting recent breakthroughs in the field.

In this edition, we will zoom in on recent investments specifically within the in-vitro diagnostics (IVD) sector. The IVD market has witnessed notable rounds of funding, reflecting the growing interest and confidence in this field.

If you're interested in contributing to an upcoming edition or collaborating with us, we welcome you to get in touch without hesitation.

Camena Bioscience closes $10m Series A financing as demand for DNA synthesis technology increases

Camena Bioscience , a synthetic biology company that supplies genes to the pharmaceutical and biotechnology sectors, announced the successful closure of a Series A funding round, raising $10 million. This financing round, led by Mercia Asset Management PLC , will be instrumental in expanding the company's operations and advancing the development of its groundbreaking DNA synthesis platform, gSynth.

Camena stands out as the pioneer in offering an exceptional enzyme-based DNA synthesis technology known for its remarkable precision. In the past year, the company has secured significant revenue by entering into commercial agreements with prominent consumers of synthetic genes.

The CEO and co-founder of Camena Bioscience is Dr. Steve Harvey , an esteemed figure in genomics research. Joining him as the CSO and co-founder is Dr. Derek Stemple , a globally recognized molecular biologist who previously co-founded TwistDX, which was acquired by Alere Inc. (now part of 雅培 ) in 2010.

Furthermore, Camena Bioscience has welcomed Aditya Rajagopal to its Board. Aditya is the founder and CTO of ChromaCode, Inc. , a diagnostics company specializing in the development of scalable and cost-effective cancer tests. He also serves as the co-founder and Executive Chairman of Esperto Medical , a venture-backed company dedicated to creating non-invasive vital sign monitors.

Collaboration of the week: Prenetics & Dennis Lo partner on a $200M Deal to Form Multi-Cancer Screening Firm

Prenetics who specializes in genomics-driven health has entered into a joint venture worth $200 million with Dennis Lo , a renowned expert in non-invasive prenatal testing and liquid biopsy. The purpose of this collaboration is to develop and bring to market an innovative early-detection screening test for multiple types of cancer.

The joint venture, named Insighta, is a 50/50 partnership with a valuation of $200 million. It stands as the largest privately-held life sciences deal in Hong Kong and one of the largest in the region. Prenetics will contribute $100 million in cash and stock, while Dennis Lo will provide his expertise and intellectual property.

insighta is led by Dennis Lo as the chairman and Danny Yeung as the CEO. Dennis Lo holds a professorship at the Li Ka Shing Faculty of Medicine at the 香港中文大学 (CUHK) and serves as the scientific director of the Center for Novostics. Danny Yeung , the CEO of Prenetics, has a strong background in genomics and precision oncology.

According to a statement, Insighta's cancer screening products will be based on Fragma, a breakthrough technology developed by a team led by Dennis Lo. Fragma examines the fragmentation patterns of cell-free DNA, serving as a promising approach for cancer detection and diagnosis.

New to the market: Delve Bio Raises $35M in Series A Financing to Develop Metagenomic Sequencing Diagnostics

Delve Bio has secured $35 million through a successful Series A funding round to bolster the advancement of their metagenomic sequencing (mNGS) platform, designed specifically for diagnosing infectious diseases.

The foundation of Delve Bio's testing platform lies in cutting-edge technology originating from the University of California San Francisco (UCSF) Center for Next-Gen Precision Diagnostics.

“While genomic testing has been transformative for oncology, rare disease, and women’s health, infectious disease has been largely overlooked,” Bradley Murray , co-founder and CEO of Delve, said in a statement. “We formed Delve Bio with the vision of bringing infectious disease diagnostics into the genomics era, enabling patients with complex – and often life-threatening – infections, which cannot be routinely diagnosed, to get a definitive diagnosis.”

Xontogeny led the financing round and was joined by S32 and GV.

Delve Bio was founded by Drs. Charles Chiu , Joseph DeRisi , Michael Wilson, Pardis Sabeti , and Matthew Meyerson , who are experts in genomics, metagenomics, and infectious disease.

The Latest in IVD:

??? Heinz Steneberg has joined? Molecular Testing Labs ?as Vice President of Regulatory Affairs!

?? Bio-Techne to Acquire Swiss Spatial Biology Firm Lunaphore

?? Exact Sciences Releases Next-Gen Cologuard Data, Inks New Partnerships

?? CENTOGENE Gets $30M Loan From Lifera, Forms Saudi Arabian JV to Broaden Access to Multiomic Testing

?? Personalis, Inc. Sues Foresight Diagnostics Diagnostics Again Alleging Patent Infringement

?? Mainz Biomed Secures $50M Prepaid Agreement, $5.5M Promissory Note

?? Helio Genomics Sister Firm LAMH Receives NMPA Approval in China for Blood-Based Liver Cancer Test

?? Novacyt Group to Acquire Yourgene Health for ￡16.7M in Cash

?? Invivoscribe , Complete Genomics Genomics Partner to Develop, Commercialize Oncology Biomarker Tests

?? Illumina Appeals FTC's Order to Divest GRAIL , Cites Government Overreach

?? Acutis Diagnostics Gets FDA Emergency Use Authorization for COVID-19 RT-PCR Test

?? Biocartis Laying Off 140 Employees as Part of Reorganization Plan

Do you have any thoughts, or news to share? Join the conversation on LinkedIn by following the hashtag?#InVitroInsider, and follow my page to participate in biweekly polls to share your insight!

If you're looking to add exceptional talent to your team or seeking new opportunities in the industry, please feel free to reach out to me!?